Concerns Raised Over Vision Loss Linked to GLP-1 Drugs
GLP-1 drugs like Wegovy and Ozempic have gained popularity for their effectiveness in weight loss and diabetes management. However, recent studies have shed light on potential side effects, including issues related to vision loss.
These medications work by mimicking the effects of the glucagon-like peptide-1 hormone to regulate blood sugar, suppress appetite, and aid digestion. While they have been widely prescribed, reports of eyesight problems linked to GLP-1 drugs, particularly semaglutide, have raised concerns among health experts.
A recent study conducted by a team of researchers from Canadian universities delved into adverse event records collected by the FDA over a span of 7 years (2017-2024) to investigate cases of ischemic optic neuropathy (ION). This rare condition can lead to sudden and complete vision loss due to a lack of blood flow to the optic nerve.
The study focused on different formulations of semaglutide, including Wegovy for weight loss, Ozempic for type 2 diabetes, and Rybelsus for type 2 diabetes. The researchers found a formulation- and dose-dependent risk of ION, with Wegovy showing the strongest association among the three drugs.
While the number of reported ION cases linked to Ozempic was higher, the study emphasized the elevated risk associated with Wegovy use. Men taking semaglutide were also found to be more likely to report ION compared to women.
Experts caution that these findings are based on data from a specific FDA database and further research is needed to assess the general risk in the population using semaglutide. The study highlights the importance of evaluating the safety of anti-obesity medications, especially with their increasing usage.
As researchers continue to unravel the potential side effects of GLP-1 drugs, including vision loss, there is a growing need for comprehensive studies to ensure the safety and efficacy of these medications.
Related: Ozempic-Like Drugs May Increase Risk of Bone And Joint Conditions
The research findings have been published in the British Journal of Ophthalmology.
